Spojené štáty - angličtina - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - alogliptin benzoate (unii: een99869sc) (alogliptin - unii:jhc049lo86), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - alogliptin 12.5 mg - kazano is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use kazano is not recommended for use in patients with type 1 diabetes mellitus. kazano is contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m2 ) [see warnings and precautions (5.1)] . - acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma. - history of serious hypersensitivity reaction to alogliptin or metformin or any of the excipients in kazano, such as anaphylaxis, angioedema and severe cutaneous adverse reactions [see warnings and precautions (5.4), adverse reactions (6.2)]. risk summary limited available data with kazano or alogliptin in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk [se

Spojené štáty - angličtina - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - alogliptin benzoate (unii: een99869sc) (alogliptin - unii:jhc049lo86) - alogliptin 6.25 mg - nesina is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use nesina is not recommended for use in patients with type 1 diabetes mellitus. nesina is contraindicated in patients with a history of serious hypersensitivity to alogliptin or any of the excipients in nesina. reactions such as anaphylaxis, angioedema and severe cutaneous adverse reactions have been reported [see warnings and precautions (5.3), adverse reactions (6.2)] . risk summary limited data with nesina in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. there are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy [see clinical considerations] . no adverse developmental effects were observed when alogliptin was administered to pregnant rats and rabbits during organogenesis at exposures 180- and 149-times the 25 mg clinical dose, respectively, based on plasma drug

Izrael - angličtina - Ministry of Health

takeda israel ltd - dexlansoprazole - modified release capsules - dexlansoprazole 30 mg - dexlansoprazole - dexilant 30 is indicated in adults and in adolescents aged 12 to 17 years for the following:• maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn• short-term treatment of heartburn and acid regurgitation associated with symptomatic non-erosive gastro-oesophageal reflux disease (gord).

Izrael - angličtina - Ministry of Health

takeda israel ltd - dexlansoprazole - modified release capsules - dexlansoprazole 60 mg - dexlansoprazole - dexilant 60 is indicated in adults and in adolescents aged 12 to 17 years for the following:• treatment of erosive reflux oesophagitis

Izrael - angličtina - Ministry of Health

takeda israel ltd - human normal immunoglobulin - solution for infusion - human normal immunoglobulin 100 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - replacement therapy in adults, children and adolescents (0-18 years) in:• primary immunodeficiency syndromes with impaired antibody production • hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (cll), in whom prophylactic antibiotics have failed or are contra-indicated.• hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (mm) patients.• hypogammaglobulinaemia in patients pre- and post-allogeneic hematopoietic stem cell transplantation (hsct).

Izrael - angličtina - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - powder - lanthanum as carbonate hydrate 1000 mg - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥ 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

Izrael - angličtina - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - powder - lanthanum as carbonate hydrate 750 mg - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥ 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

Izrael - angličtina - Ministry of Health

takeda israel ltd - pantoprazole - tablets - pantoprazole 40 mg - pantoprazole - pantoprazole - short term treatment of acute duodenal ulcer. acute gastric ulcer.moderate and severe reflux oesophagitis.eradication of the helicobacter pylori in combination with clarithromycin and amoxycillin or clarithromycin and metronidazole/tinidazole or amoxycillin and metronidazole/tinidazole in cases of duodenal ulcer and gastric ulcer with the objective of reducing the recurrence of duodenal and gastric ulcers caused by this microorganism.zollinger-ellison-syndrome.

Izrael - angličtina - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - chewable tablets - lanthanum as carbonate hydrate 500 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

Izrael - angličtina - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - chewable tablets - lanthanum as carbonate hydrate 750 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.